Biotech company Amgen won a major victory Oct. 3 when the U.S. District Court in Boston issued a permanent injunction prohibiting Roche from selling Amgen’s renal anemia drug, Mircera, in the U.S. The court had already entered a preliminary injunction preventing Roche from selling the drug, but Roche appealed the ruling. The court has now stated that it would enter a permanent injunction once the appeal of the preliminary injunction is resolved. “Amgen is pleased with today’s ruling, which recognizes that Amgen is entitled to a permanent injunction against Roche and reaffirms the infringement and validity of our patents,” stated David Scott, senior vice president and general counsel at Amgen, which is based in Thousand Oaks.
